Indian Government Extends Deadline for Registration and Monthly Declaration of Tobacco Products

Regulations by 2FIRSTS.ai
Apr.12.2024
Indian Government Extends Deadline for Registration and Monthly Declaration of Tobacco Products
Indian government extends deadline for special registration and monthly declaration process for manufacturers of betel, chewable tobacco, and tobacco products.

According to a report by The Hindu Business Line on April 11, the Indian government has extended the deadline for the implementation of special registration and monthly reporting procedures for manufacturers of betel nut, chewing tobacco, and tobacco products until May 15th.

 

In January, the Central Board of Indirect Taxes and Customs (CBIC) announced new registration and monthly reporting procedures set to be implemented starting on April 1, 2024. The regulations require manufacturers of betel nuts, chewing tobacco, and tobacco products who fail to register their packaging processes with the Goods and Services Tax (GST) authorities by April 1 to pay fines of up to 100,000 rupees (1199 USD), with the penalty terms yet to be announced. However, a recent CBIC notification extended the implementation date of this special program by 45 days, until May 15th.

 

The new regulations require tobacco product manufacturers to electronically fill out Form GST SRM-I within 30 days of the effective date of May 15, 2024, providing detailed information on the packaging machines used for filling and packaging. The special declaration form (GST SRM-II) must also be submitted by the 10th of next month.

 

The Government of Malaysia (GoM) stated that tax evasion on tobacco products is a common practice internationally, and this regulation plays a role in enhancing compliance by strengthening enforcement and administrative mechanisms to curb tax evasion.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

South Korea online purchasing fuels spread among younger groups; online drug cases share climbs
South Korea online purchasing fuels spread among younger groups; online drug cases share climbs
Police said detections of new drugs disguised as e-cigarettes reached 1,206 cases through September last year, up from 941 in 2022, and the number of detected drug types increased from 26 to 33 over the same period.
Feb.11 by 2FIRSTS.ai
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
Philip Morris International said it presented scientific evidence to the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee to support its ZYN nicotine pouches seeking a modified risk tobacco product designation, which would allow the company to communicate to adult smokers that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
Jan.26 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire Q2 FY2026 revenue falls to $20.3M as it trims lower-quality customers; A/R down nearly 20%
Ispire reported a sharp year-on-year revenue decline in Q2 FY2026 as it shifted away from lower-quality customers, while cutting operating expenses and narrowing its net loss. The company also highlighted improved collections, with net accounts receivable down nearly one-fifth since June 30, 2025, alongside ongoing manufacturing and technology initiatives.
Feb.09 by 2FIRSTS.ai